Board of Directors
Paul Harper PhD
Chairman
Tim Mitchell PhD
Founder: CEO
John Reader PhD
Founder: VP Chemistry
Paul Harper PhD
Non-Executive Chairman
Dr Paul Harper, aged 60, has over 30 years' experience in the life sciences industry covering both drug development and medical devices. Paul has served as Chief Executive of Cambridge Antibody Technology Limited, and Provensis Limited. He has also served as Corporate Development Director of Unipath Limited, then the medical diagnostics business of Unilever PLC, and as Director of Research and Development for Johnson & Johnson Limited. Formerly head of Antimicrobial Chemotherapy for Glaxo PLC, Paul has a PhD in Molecular Virology and is the author of over 50 publications.
Tim Mitchell PhD
Founder and CEO.
Dr Tim Mitchell, aged 46, has 18 years' experience in the industry with key management and business expertise gained from his positions at Cambridge Discovery Chemistry and his roles at Millennium as a member of the management team and in forming the integrated Structure-Based Discovery department.
As Director of the Millennium Structure-Based Discovery department, Tim was responsible for global provision of Protein Structure and High Throughput Chemical Synthesis for Millennium as well as for local Computational Chemistry, Informatics and Automation capabilities. Prior to that, he was Director of Computational Chemistry at Cambridge Discovery Chemistry Ltd, and a team leader in the Computational and Structural Sciences department at SmithKline Beecham Pharmaceuticals. Tim has a PhD in Computational Chemistry and a BSc in Chemistry.
John Reader PhD
Founder and VP Chemistry
Dr John Reader, aged 40, has 13 years' experience within the industry and was formerly Associate Director, Chemical Technologies at Millennium Pharmaceuticals Research and Development Ltd, prior to which he worked with Pharmacopeia Inc. and Cambridge Discovery Chemistry in the provision of high throughput chemistry services to external and internal clients.
John has extensive experience of leading large research teams and in the invention and application of new technologies to the drug-discovery process, with an excellent track record of delivering successful projects to clients and has authored or co-authored many patents and publications. The majority of patents granted to John cover composition of matter discovered in the multiple projects in which he has worked, with further patents covering technological innovations in the field. John is a member of the EPSRC Peer Review College and has a PhD in Chemistry and a BSc in Applied Chemistry.
Requires RSS news reader
Requires MS Word
Requires Adobe Acrobat Reader